Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: A population-based case-control study

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 358-364

  Koomen, E R ^a   Joosse, A ^a   Herings, R M C ^b   Casparie, M K ^c   Guchelaar, H J ^a   Nijsten, T ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PHARMO   (Netherlands)

^c Foundation PALGA   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Estrogens; Hormonal replacement therapy; Incidence; Melanoma; Oral contraceptives

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; MESTRANOL; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MELANOMA; NETHERLANDS; ORAL CONTRACEPTION; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; CONTRACEPTIVES, ORAL; DATABASES, FACTUAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MELANOMA; MULTIVARIATE ANALYSIS; NETHERLANDS; ODDS RATIO; POPULATION SURVEILLANCE; RISK FACTORS; SKIN NEOPLASMS;

EID: 60549100903     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn589     Document Type: Article

References (30)

1. Østerlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer 1988; 42: 821-824.
2. Karagas MR, Stukel TA, Dykes J et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer 2002; 86: 1085-1092.
3. de Vries E, Nijsten TEC, Visser O et al. Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol 2008; 19(3): 583-589.
4. de Vries E, Houterman S, Janssen-Heijnen MLG et al. Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the southeast of The Netherlands. Ann Oncol 2007; 18: 1110-1116.
5. Koomen ER, Joosse A, Herings RMC et al. Is statin use associated with a reduced incidence, reduced Breslow thickness or delayed metastasis of melanoma of the skin? Eur J Cancer 2007; 43: 2580-2589.
6. Schoenberg BS, Christine BW. Malignant melanoma associated with breast cancer. South Med J 1980; 73(11): 1493-1497.
7. Walker MJ, Beattie CW, Patel MK et al. Estrogen receptor in malignant melanoma. J Clin Oncol 1987; 5(8): 1256-1261.
8. Beral S, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California. Br J Cancer 1977; 36: 804-809.
9. Kay CR. Malignant melanoma and oral contraceptives. Br J Cancer 1981; 44: 479.
10. Ramcharan S, Pellegrin FA, Ray R, Hsu JP. The Walnut Creek Contraceptive Drug Study: A Prospective Study of the Side Effects of Oral Contraceptives III. NIH Publication No. 81-564 an interim report: A comparison of disease occurrence leading to hospitalization or death in users and nonusers of oral contraceptives. J Reprod Med 1980; 25(6 Suppl): 345-372.
11. Adam SA, Sheaves JK, Wright NH et al. A case-control study of the possible association between oral contraceptives and malignant melanoma. Br J Cancer 1981; 44: 45-50.
12. Zanetti R, Francheschi S, Rossa S et al. Cutaneous malignant melanoma in females: The role of hormonal and reproductive factors. Int J Epidemiol 1990; 19(3): 522-526.
13. Hannaford PC, Villard-Mackintosh L, Vessey MP, Kay CR. Oral contraceptives and malignant melanoma. Br J Cancer 1991; 63: 430-433.
14. Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women. III. Reproductive factors and oral contraceptive use. Am J Epidemiol 1995; 141(10): 943-950.
15. Westerdahl J, Olsson H, Måsbäck A et al. Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors. Br J Cancer 1996; 73: 1126-1131.
16. Feskanich D, Hunter DJ, Willett WC et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer 1999; 81(5): 918-923.
17. Palmer JR, Rosenberg L, Strom BL et al. Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes and Control 1992; 3: 547-554.
18. Leê MG, Cabanes PA, Desvignes V et al. Oral contraceptive use and risk of cutaneous malignant melanoma in case-control study of French women. Cancer Causes and Control 1992; 3: 199-205.
19. PHARMO pharmacy database. http://www.pharmo.nl/ (23 November 2007, date last accessed).
20. Lau HS, de Boer A, Beuning KS et al. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997; 50: 619-625.
21. Herings R. Pharmo, A Record Linkage System for Postmarketing Surveillance of Prescription Drugs in the Netherlands [Thesis in Pharmaco-Epidemiology and Pharmacotherapy]. The Netherlands: Utrecht University 1993; 17-32.
22. Casparie MK, Tiebosch T, Burger G et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007; 29(1): 19-24.
23. Vandenbroucke JP, Von Elm E, Altman DG et al. Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. Ann Intern Med 2007; 147: 163-194.
24. LeBoit PE, Burg G, Weedon D, Sarasin A (eds): WHO Classification of Tumours Volume 6, IARC WHO Classification of Tumours No 6, Pathology and Genetics of Tumours of the Skin. Lyon, France: IARC Press 2005.
25. Freeman SR, Drake AL, Heilig LF et al. Statins, fibrates, and melanoma risk: A systematic review and meta-analysis. J Natl Cancer Inst 2006; 98(21): 1538-1546.
26. de Vries E, van de Poll-Franse LV, Louwan WJ et al. Predictions of skin cancer incidence in The Netherlands up to 2015. Br J Dermatol 2005; 152: 481-488.
27. Centraal Bureau voor de Statistiek. http://www.statline.cbs.nl/ (18 February 2007, date last accessed).
28. Dobos J, Timar J, Bocsi J et al. In vitro and in vivo antitumor effect of 2-methoxyestradiol on human melanoma. Int J Cancer 2004; 112: 771-776.
29. Egan KM, Sosman JA, Blott WJ. Sunlight and reduced risk of cancer: Is the real story vitamin D? J Natl Cancer Inst 2005; 97(3): 161-163.
30. Jensen LB, Hilden J. Sociological and behavioral characteristics of perimenopausal women with an express attitude to hormone substitution therapy. Maturitas 1996; 23: 73-83.